GSK wants to double Shingrix sales, and a new FDA okay could...

The FDA has approved GlaxoSmithKline's shingles vaccine Shingrix for use in people aged under 50 who are immunocompromised – a key step in the UK drugmaker's plan to build the shot into a £

Vaccine sales recover at GSK in Q3, but lockdown fears weigh...

GlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the second as a result of the COVID-19 pandemic, putting it back on course to meet the lower end

GSK starts 2020 on a high, but warns of tougher times ahead

Shingrix and Trelegy shield GSK from Advair fallout

Shingles vaccine boosts GSK as generic Advair bites

GSK’s first quarter sales beat estimates, helped along by shingles vaccine Shingrix and partly offsetting the effect of declining Advair sales.

FDA approval gained, Glaxo awaits key committee blessing for...

The FDA granted approval to GSK's new shingles vaccine Shingrix on Friday, giving the company the green light on one of its important new products.